Sunday , 24 September 2017

Home » RESOURCES » INVESTING » Agios Pharma shares dive after anemia treatment development halted

Agios Pharma shares dive after anemia treatment development halted

Agios Pharmaceuticals Inc. shares fell after the drug developer said it is no longer pursuing a second drug candidate to treat a rare form of anemia. Agios shares dropped 19% to $45.55 after hours. The company said it will no longer develop the AG-519 treatment for pyruvate kinase deficiency, an inherited condition where gene mutations from each parent cause an accelerated destruction of red blood cells, after the Food and Drug Administration put a clinical study of the drug on hold. Agios said the decision does not affect the development of another drug candidate, AG-348, for the condition.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Agios Pharma shares dive after anemia treatment development halted Reviewed by on . Agios Pharmaceuticals Inc. shares fell after the drug developer said it is no longer pursuing a second drug candidate to treat a rare form of anemia. Agios shar Agios Pharmaceuticals Inc. shares fell after the drug developer said it is no longer pursuing a second drug candidate to treat a rare form of anemia. Agios shar Rating:
scroll to top